Valens Pharma Ltd.

Edmonton-based Valens Pharma Ltd., is a privately held, late-stage, biopharmaceutical company focused on commercializing drug product candidates in the novel class of energy metabolism agents, referred to as PDK blockers. The Company's technology is focused on metabolic modulation, through the use of dichloroacetate (DCA) and related compounds, which improve energy production by favouring glucose metabolism. In addition to "DCA i.v." the Company has exciting earlier stage compounds intended to target the treatment of cardiovascular disease, and related metabolic conditions (e.g., diabetes). Cardiovascular disease is the "number one" cause of death in North America, and each year in the United States alone, over 650,000 open heart surgeries are conducted.